2012-2013 Influenza Season
Week 16 ending April 20, 2013

All data are preliminary and may change as more reports are received.

Synopsis: During week 16 (April 14-20, 2013), influenza activity decreased in the United States.

- **Viral Surveillance**: Of 3,384 specimens tested and reported by collaborating laboratories, 250 (7.4%) were positive for influenza.
- **Pneumonia and Influenza Mortality**: The proportion of deaths attributed to pneumonia and influenza (P&I) was below the epidemic threshold.
- **Influenza-Associated Pediatric Deaths**: Five pediatric deaths were reported.
- **Influenza-Associated Hospitalizations**: A cumulative rate for the season of 43.9 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported. Of reported hospitalizations, 50% were among adults 65 years and older.
- **Outpatient Illness Surveillance**: The proportion of outpatient visits for influenza-like illness (ILI) was 1.1%. This is below the national baseline of 2.2%. All 10 regions reported ILI below region-specific baseline levels. One state experienced low activity; 49 states and New York City experienced minimal activity, and the District of Columbia had insufficient data.
- **Geographic Spread of Influenza**: Three states reported widespread influenza activity; 3 states reported regional influenza activity; 8 states reported local influenza activity; the District of Columbia, Guam, Puerto Rico, and 35 states reported sporadic influenza activity; 1 state reported no influenza activity, and the U.S. Virgin Islands did not report.

A description of surveillance methods is available at: [http://www.cdc.gov/flu/weekly/overview.htm](http://www.cdc.gov/flu/weekly/overview.htm).

### National and Regional Summary of Select Surveillance Components

<table>
<thead>
<tr>
<th>HHS Surveillance Regions*</th>
<th>Data for current week</th>
<th>Data cumulative since September 30, 2012 (Week 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Outpatient ILI†</td>
<td>% positive for flu‡</td>
</tr>
<tr>
<td>Nation</td>
<td>Normal</td>
<td>7.4%</td>
</tr>
<tr>
<td>Region 1</td>
<td>Normal</td>
<td>16.1%</td>
</tr>
<tr>
<td>Region 2</td>
<td>Normal</td>
<td>17.7%</td>
</tr>
<tr>
<td>Region 3</td>
<td>Normal</td>
<td>15.5%</td>
</tr>
<tr>
<td>Region 4</td>
<td>Normal</td>
<td>12.9%</td>
</tr>
<tr>
<td>Region 5</td>
<td>Normal</td>
<td>17.1%</td>
</tr>
<tr>
<td>Region 6</td>
<td>Normal</td>
<td>3.7%</td>
</tr>
<tr>
<td>Region 7</td>
<td>Normal</td>
<td>5.1%</td>
</tr>
<tr>
<td>Region 8</td>
<td>Normal</td>
<td>5.3%</td>
</tr>
<tr>
<td>Region 9</td>
<td>Normal</td>
<td>16.4%</td>
</tr>
<tr>
<td>Region 10</td>
<td>Normal</td>
<td>5.5%</td>
</tr>
</tbody>
</table>

* [http://www.hhs.gov/about/regionmap.html](http://www.hhs.gov/about/regionmap.html)
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline.
‡ National data are for current week; regional data are for the most recent three weeks.
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands.
**U.S. Virologic Surveillance:** U.S. World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System (NREVSS) collaborating laboratories located in all 50 states and Puerto Rico report to CDC the number of respiratory specimens tested for influenza and the number positive by influenza virus type and influenza A virus subtype.

<table>
<thead>
<tr>
<th>Week 16</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of specimens tested</strong></td>
<td>3,384</td>
</tr>
<tr>
<td><strong>No. of positive specimens (%)</strong></td>
<td>250 (7.4%)</td>
</tr>
<tr>
<td><strong>Positive specimens by type/subtype</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Influenza A</strong></td>
<td></td>
</tr>
<tr>
<td><strong>2009 H1N1</strong></td>
<td>14 (15.9%)</td>
</tr>
<tr>
<td><strong>Subtyping not performed</strong></td>
<td>37 (42.0%)</td>
</tr>
<tr>
<td><strong>H3</strong></td>
<td>37 (42.0%)</td>
</tr>
<tr>
<td><strong>Influenza B</strong></td>
<td>162 (64.8%)</td>
</tr>
</tbody>
</table>

Influenza-Positive Tests Reported to CDC by U.S. WHO/NREVSS Collaborating Laboratories, National Summary, 2012-13 Season

The image below shows the proportion of influenza-positive respiratory samples by type and subtype for the most recent three weeks in each region. Regions with ILI above region-specific baseline levels are highlighted. Region-specific data can be found at [http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html](http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html).
Antigenic Characterization: CDC has antigenically characterized 2,209 influenza viruses [210 2009 H1N1 viruses, 1,264 influenza A (H3N2) viruses, and 735 influenza B viruses] collected by U.S. laboratories since October 1, 2012.

2009 H1N1 [210]

- 207 (98.6%) of the 210 2009 H1N1 viruses tested were characterized as A/California/7/2009-like, the influenza A (H1N1) component of the 2012-2013 influenza vaccine for the Northern Hemisphere.
- 3 (1.4%) of the 210 2009 H1N1 viruses tested showed reduced titers with antiserum produced against A/California/7/2009.

Influenza A (H3N2) [1,264]:

- 1,260 (99.7%) of the 1,264 H3N2 influenza viruses tested have been characterized as A/Victoria/361/2011-like, the influenza A (H3N2) component of the 2012-2013 Northern Hemisphere influenza vaccine.
- 4 (0.3%) of the 1,264 H3N2 viruses tested showed reduced titers with antiserum produced against A/Victoria/361/2011.

Influenza B (B/Yamagata/16/88 and B/Victoria/02/87 lineages) [735]:

- Yamagata Lineage [494]: 494 (67.2%) of the 735 influenza B viruses tested so far this season have been characterized as B/Wisconsin/1/2010-like, the influenza B component of the 2012-2013 Northern Hemisphere influenza vaccine.
- Victoria Lineage [241]: 241 (32.8%) of 735 influenza B viruses tested have been from the B/Victoria lineage of viruses.
Composition of the 2013-2014 Influenza Vaccine: The World Health Organization (WHO) has recommended vaccine viruses for the 2013-2014 Northern Hemisphere vaccines, and the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made recommendations for the composition of the 2013-2014 influenza vaccines to be used in the United States. Both agencies recommend that trivalent vaccines contain an A/California/7/2009-like (2009 H1N1) virus, an A(H3N2) virus antigenically like the cell-propagated, or cell-grown, virus A/Victoria/361/2011 (A/Texas/50/2012), and a B/Massachusetts/2/2012-like (B/Yamagata lineage) virus. It is recommended that quadrivalent vaccines containing an additional influenza B virus contain a B/Brisbane/60/2008-like (B/Victoria lineage) virus in addition to the viruses recommended for the trivalent vaccines. These recommendations were based on global influenza virus surveillance data related to epidemiology and antigenic characteristics, serological responses to 2012-2013 seasonal vaccines, and the availability of candidate strains and reagents.

Antiviral Resistance: Testing of 2009 H1N1, influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a functional assay. Additional 2009 influenza A (H1N1) clinical samples are tested for a single mutation in the neuraminidase of the virus known to confer oseltamivir resistance (H275Y). The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B viruses). As a result, data from adamantane resistance testing are not presented below.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2012

<table>
<thead>
<tr>
<th>Virus</th>
<th>Oseltamivir</th>
<th>Zanamivir</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Virus Samples tested (n)</td>
<td>Resistant Viruses, Number (%)</td>
</tr>
<tr>
<td>Influenza A</td>
<td>1,843*</td>
<td>2 (0.1)</td>
</tr>
<tr>
<td>(H3N2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza B</td>
<td>842</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>2009 H1N1</td>
<td>504*</td>
<td>2 (0.4)</td>
</tr>
</tbody>
</table>

*Includes specimens tested in national surveillance and additional specimens tested at public health laboratories in 11 states (AZ, DE, HI, ME, MD, MI, MN, NY, PA, WA, and WI) who share testing results with CDC.

The majority of currently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications, oseltamivir and zanamivir; however, rare sporadic cases of oseltamivir-resistant 2009 H1N1 and A (H3N2) viruses have been detected worldwide. Antiviral treatment with oseltamivir or zanamivir as early as possible is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at greater risk for serious influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at http://www.cdc.gov/flu/antivirals/index.htm.
**Novel Influenza A Virus:** No new human infections with novel influenza A viruses in the United States were reported to CDC during week 16.

On April 1, 2013, the World Health Organization (WHO) first reported 3 human infections with a new influenza A (H7N9) virus in China. Since then, additional cases have been reported. Most reported cases have severe respiratory illness and, in some cases, have died. At this time, no cases of H7N9 outside of China have been reported. The new H7N9 virus has not been detected in people or birds in the United States.

**Pneumonia and Influenza (P&I) Mortality Surveillance:** During week 16, 6.7% of all deaths reported through the 122 Cities Mortality Reporting System were due to P&I. This percentage was below the epidemic threshold of 7.3% for week 16.

**Pneumonia and Influenza Mortality for 122 U.S. Cities**  
**Week ending April 20, 2013**
Influenza-Associated Pediatric Mortality: Five influenza-associated pediatric deaths were reported to CDC during week 16. One death was associated with an influenza A virus for which the subtype was not determined and occurred during week 16 (week ending April 13, 2013) and four deaths were associated with influenza B viruses and occurred during weeks 3, 13, 14, and 15 (weeks ending January 19, March 30, April 6, and April 13, 2013).

A total of 131 influenza-associated pediatric deaths have been reported during the 2012-2013 season from Chicago [1], New York City [4] and 37 states (AL [1], AR [4], AZ [3], CA [4], CO [5], FL [8], GA [2], HI [2], IA [1], IL [1], IN [4], KS [2], KY [2], LA [2], MA [4], MD [3], ME [1], MI [6], MN [4], MS [1], NE [1], NH [3], NJ [7], NM [3], NV [1], NY [9], OH [4], OK [1], PA [1], SC [4], SD [3], TN [3], TX [17], UT [3], VA [1], WA [1], and WI [4]).

Additional data can be found at http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html

Number of Influenza-Associated Pediatric Deaths by Week of Death: 2009-10 season to present

Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) and adults (since the 2005-2006 influenza season).

The FluSurv-NET covers more than 80 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and additional Influenza Hospitalization Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance
during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT during the 2011-2012 season; and IA, MI, OH, RI, and UT during the 2012-2013 season.

Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and describe characteristics of persons hospitalized with severe influenza illness. The rates provided are likely to be an underestimate as influenza-related hospitalizations can be missed, either because testing is not performed, or because cases may be attributed to other causes of pneumonia or other common influenza-related complications.

Between October 1, 2012 and April 13, 2013, 12,250 laboratory-confirmed influenza-associated hospitalizations were reported. This is a rate of 43.9 per 100,000 population. The most affected group is those ≥65 years, accounting for 50% of reported cases. Among all hospitalizations, 9,729 (79.4%) were associated with influenza A and 2,439 (19.9%) with influenza B. There was no virus type information for 44 (0.4%) hospitalizations. Among hospitalizations with influenza A subtype information, 3,575 (96.1%) were attributed to H3 and 136 (3.7%) were attributed to 2009 H1N1. The most commonly reported underlying medical conditions among hospitalized adults were cardiovascular disease, metabolic disorders, obesity, and chronic lung disease (excluding asthma). The most commonly reported underlying medical conditions in hospitalized children were asthma, neurologic disorders, and immune suppression. Approximately 44% of hospitalized children had no identified underlying medical conditions. Among 572 hospitalized women of childbearing age (15-44 years), 175 were pregnant, including 7 pregnancies among the 33 pediatric cases in this category.

Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and http://gis.cdc.gov/grasp/fluview/FluHospChars.html
Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart failure, and pulmonary hypertension (does not include isolated hypertension); Chronic lung diseases include conditions such as bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease; Immune suppression includes conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications; Metabolic disorders include conditions such as diabetes mellitus, thyroid dysfunction, adrenal insufficiency, and liver disease; Neurologic diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction; Neuromuscular diseases include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if indicated in patient’s medical chart or if body mass index (BMI) >30 kg/m²; Pregnancy percentage calculated using number of female cases aged between 15 and 44 years of age as the denominator; Renal diseases include conditions such as acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance; No known condition indicates that the case did not have any known underlying medical condition indicated in medical chart at the time of hospitalization.

Only includes cases for which data collection has been completed through the medical chart review stage.
Outpatient Illness Surveillance: Nationwide during week 16, 1.1% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is below the national baseline of 2.2%.

(ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.)

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2012-13 and Selected Previous Seasons

On a regional level, the percentage of outpatient visits for ILI ranged from 0.4% to 2.0% during week 16. All 10 regions reported a proportion of outpatient visits for ILI below their region-specific baseline levels.

Additional data can be found at [http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html](http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html)
Region 1 - CT, ME, MA, NH, RI, VT

Region 2 - NJ, NY, USVI

Region 3 - DE, DC, MD, PA, VA, WV

Region 4 - AL, FL, GA, KY, MS, NC, SC, TN

Region 5 - IL, IN, MI, MN, OH, WI

Region 6 - AR, LA, NM, OK, TX

Region 7 - IA, KS, MO, NE

Region 8 - CO, MT, ND, SD, UT, WY

Region 9 - AZ, CA, HI, NV

Region 10 - AK, ID, OR, WA

NOTE: Scales differ between regions
*Use of the regional baselines for state data is not appropriate.
**ILINet Activity Indicator Map:** Data collected in ILINet are used to produce a measure of ILI activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI and are compared to the average percent of ILI visits that occur during spring and fall weeks with little or no influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity from outpatient clinics being below the average, to high, which would correspond to ILI activity from outpatient clinics being much higher than average.

During week 16, the following ILI activity levels were experienced:

- One state experienced low ILI activity (Vermont).
- Data were insufficient to calculate an ILI activity level for the District of Columbia.

*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.

Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state.

Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.
Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses, but does not measure the severity of influenza activity.

During week 16, the following influenza activity was reported:

- Widespread influenza activity was reported by 3 states (Connecticut, Massachusetts, and New York).
- Regional influenza activity was reported by 3 states (New Hampshire, New Jersey, and Pennsylvania).
- Local influenza activity was reported by 8 states (Alaska, Arizona, Louisiana, Maine, Michigan, Ohio, Oklahoma, and Virginia).
- One state (Georgia) reported no influenza activity.
- The U.S. Virgin Islands did not report.

*This map indicates geographic spread & does not measure the severity of influenza activity*
Additional National and International Influenza Surveillance Information

FluView Interactive: This season, FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools visit www.cdc.gov/flu/weekly/fluviewinteractive.htm.

U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information.

Alabama  Alaska  Arizona  Arkansas  California
Colorado  Connecticut  Delaware  District of Columbia  Florida
Georgia  Hawaii  Idaho  Illinois  Indiana
Iowa  Kansas  Kentucky  Louisiana  Maine
Maryland  Massachusetts  Michigan  Minnesota  Mississippi
Missouri  Montana  Nebraska  Nevada  New Hampshire
New Jersey  New Mexico  New York  North Carolina  North Dakota
Ohio  Oklahoma  Oregon  Pennsylvania  Rhode Island
South Carolina  South Dakota  Tennessee  Texas  Utah
Vermont  Virginia  Washington  West Virginia  Wisconsin
Wyoming  New York City  Virgin Islands

Google Flu Trends: Google Flu Trends uses aggregated Google search data in a model created in collaboration with CDC to estimate influenza activity in the United States. For more information and activity estimates from the U.S. and worldwide, see http://www.google.org/flutrends/.

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza located in Australia, China, Japan, and the United Kingdom.


Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at http://www.phac-aspc.gc.ca/fluwatch/.

Health Protection Agency (United Kingdom): The most up-to-date influenza information from the United Kingdom is available at http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.